Boston Scientific Corporation acquires Silk Road Medical, Inc. (2024)

Deal facts

Buyer: Boston Scientific Corporation
Target: Silk Road Medical, Inc.
Deal value: Not disclosed
Announced: 17 June 2024
Status: Completed
Sector: Healthcare
Country: United States
Consideration: cash

Sources

SEC_EDGAR_8K

What we know

Weekly digest

Join Exit Mode Insider

Ten deal briefs a week, founder commentary, and the patterns worth paying attention to.

Join Exit Mode Insider, £12/mo

Deal timeline

1 update

17 Sept 2024CompletedClosed
Boston Scientific Corporation completes acquisition of Silk Road Medical, Inc.
Introductory Note This Current Report on Form 8-K is being filed in connection with the consummation on September 17, 2024 (the “Closing Date”) of the transaction contemplated by that certain Agreement and Plan of Merger, dated June 17, 2024 (the “Merger Agreement”), by and among Boston Scientific Corporation, a Delaware corporation (“Boston Scientific”), Seminole Merger Sub, Inc., a Delaware corp
Source

OpinionExit Mode editorial

We see a clear signal in the recent completion of Boston Scientific Corporation's acquisition of Silk Road Medical, Inc. This transaction, announced on 17 June 2024, represents a definitive shift from public markets to private ownership within the healthcare sector. The deal structure is straightforward: a cash consideration that removes the target from public scrutiny and places it under the control of a larger industrial player. For the SME founder watching from the sidelines, this move highlights a persistent trend where established medical device giants prefer to internalise innovation rather than compete with it on the open exchange.

The decision to execute a going-private transaction via an all-cash deal carries specific mechanical implications. By opting for cash, the buyer eliminates the need for shareholder approval processes that often accompany stock-for-stock swaps, thereby accelerating the path to completion. This approach also sidesteps the volatility of public markets, which can derail negotiations when share prices fluctuate. In the UK and EU regulatory context, such a move would still trigger a thorough review by the Competition and Markets Authority or the European Commission to ensure no anti-competitive effects arise, given the consolidation of market share in the vascular intervention space. While the US jurisdiction applies its own antitrust thresholds, the principle remains that a cash deal signals a buyer confident in the strategic fit and willing to commit immediate liquidity to secure the asset.

We believe this deal underscores the value of timing and structure for founders seeking an exit. The all-cash nature of the consideration provides certainty of value, a stark contrast to deals laden with earn-outs or contingent payments that often leave sellers exposed to future operational performance. The buyer has taken the risk on integration, allowing the target to focus on R&D without the quarterly earnings pressure of a public listing. This is a pragmatic path for companies with strong technology but limited capital to scale globally.

Your immediate takeaway is to audit your current capital structure against your exit timeline. If your growth strategy requires significant capital expenditure that public markets are currently reluctant to fund, explore how a private equity or strategic buyer might offer a cleaner, cash-based exit route that avoids the dilution and disclosure burdens of staying public.

Editorial opinion. Not financial or legal advice.

Explore

Browse adjacent archives

Jump from this deal into the sector, buyer, deal type, and year views that carry the strongest contextual signal.

More Healthcare deals More 2024 deals More going private deals More from Boston Scientific Corporation All M&A deals

Similar deals

Other Healthcare M&A activity tracked by Exit Mode.

5 May 2026CompletedHealthcare

Merck to acquire Terns Pharmaceuticals, Inc.

Merck and Terns Pharmaceuticals, Inc. entered the Exit Mode archive.

Buyer: Merck
Target: Terns Pharmaceuticals, Inc.
Deal value: Not disclosed
Deal type: going private

Read deal Healthcare deals going private deals United States deals

27 April 2026CompletedHealthcare

BioMarin Pharmaceutical Inc. to acquire Amicus Therapeutics, Inc.

BioMarin Pharmaceutical Inc. and Amicus Therapeutics, Inc. entered the Exit Mode archive.

Buyer: BioMarin Pharmaceutical Inc.
Target: Amicus Therapeutics, Inc.
Deal value: Not disclosed
Deal type: going private

Read deal Healthcare deals going private deals United States deals

23 April 2026CompletedHealthcare

Servier to acquire Day One Biopharmaceuticals, Inc.

Servier and Day One Biopharmaceuticals, Inc. entered the Exit Mode archive.

Buyer: Servier
Target: Day One Biopharmaceuticals, Inc.
Deal value: USD 2,500,000,000
Deal type: going private

Read deal Healthcare deals going private deals United States deals

30 March 2026CompletedHealthcare

Aurinia Pharma U.S., Inc. to acquire Kezar Life Sciences, Inc.

Aurinia Pharma U.S., Inc. and Kezar Life Sciences, Inc. entered the Exit Mode archive.

Buyer: Aurinia Pharma U.S., Inc.
Target: Kezar Life Sciences, Inc.
Deal value: Not disclosed
Deal type: going private

Read deal Healthcare deals going private deals United States deals

23 March 2026CompletedHealthcare

Abbott to acquire Exact Sciences Corp

Abbott and Exact Sciences Corp entered the Exit Mode archive.

Buyer: Abbott
Target: Exact Sciences Corp
Deal value: Not disclosed
Deal type: going private

Read deal Healthcare deals going private deals United States deals

Buyer history